Dandruff (pityriasis capitis) and seborrheic dermatitis (SD) represent a spectrum of the same condition driven by Malassezia yeast overgrowth on sebum-rich skin areas — differing in severity and inflammatory component rather than kind. Together they affect approximately 50% of adults at some point, making scalp conditions one of the most common dermatological complaints encountered in clinical practice and the pharmacy. Understanding the evidence base for scalp treatment avoids the trial-and-error approach that leaves many patients cycling through ineffective products. Our skin care catalog includes medicated scalp care products for clinical use and patient recommendation.
Evidence-Based Antifungal Shampoos
The most evidence-supported scalp treatment agents are antifungals targeting Malassezia: Ketoconazole 1% (OTC Nizoral A-D) and 2% (prescription): azole antifungal with the strongest evidence for both dandruff and SD — achieving mycological cure and symptom resolution in 70–80% of patients in RCTs. Selenium sulfide 2.5%: cytostatic antifungal with comparable evidence to ketoconazole; slightly more effective against dandruff, similar to ketoconazole for SD. Zinc pyrithione 1–2% (most commonly found in OTC anti-dandruff shampoos — Head & Shoulders): effective antifungal and anti-inflammatory; consistently superior to placebo, slightly less potent than ketoconazole or selenium sulfide. Ciclopirox olamine 1%: broad-spectrum antifungal with additional anti-inflammatory activity — evidence comparable to ketoconazole, useful for steroid-sparing management of scalp SD.
Seborrheic Dermatitis: Beyond Dandruff Management
SD — affecting not only the scalp but commonly the eyebrows, nasolabial folds, external auditory canals, and central chest — requires anti-inflammatory management in addition to antifungal treatment. Topical corticosteroid solutions (fluocinolone acetonide 0.01% shampoo, clobetasol 0.05% foam) are the most potent anti-inflammatory option for scalp SD — appropriate for flare management but not continuous long-term use (scalp skin atrophy risk). Topical calcineurin inhibitors (tacrolimus 0.1% ointment, pimecrolimus 1% cream) for facial SD — effective steroid-sparing option for chronic management on the face. Maintenance with antifungal shampoo 1–2×/week after initial control is the standard approach for preventing recurrence.
